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A B S T R A C T   
The role for localized radiation to treat ovarian cancer (OC) patients with locally recurrent vaginal/perirectal 
lesions remains unclear, though we hypothesize these patients may be salvaged locally and gain long-term 
survival benefit. We describe our institutional outcomes using intensity modulated radiation therapy (IMRT) 
+/- high-dose rate (HDR) brachytherapy to treat this population. Our primary objectives were to evaluate 
complete response rates of targeted lesions after radiation and calculate our 5-year in-field control (IFC) rate. 
Secondary objectives were to assess radiation-related toxicities, chemotherapy free-interval (CFI), as well as post- 
radiation progression-free (PFS) and overall survival (OS). PFS and OS were defined from radiation start to either 
progression or death/last follow-up, respectively. This was a heavily pre-treated cohort of 17 recurrent OC pa-
tients with a median follow-up of 28.4 months (range 4.5–166.4) after radiation completion. 52.9% had high- 
grade serous histology and 4 (23.5%) had isolated vaginal/perirectal disease. Four (23.5%) patients had in- 
field failures at 3.7, 11.2, 24.5, and 27.5 months after start of radiation, all treated with definitive dosing of 
radiation therapy. Patients who were platinum-sensitive prior to radiation had similar median PFS (6.5 vs. 13.4 
months, log-rank p = 0.75), but longer OS (71.1 vs 18.8 months, log-rank p = 0.05) than their platinum-resistant 
counterparts. Excluding patients with low-grade histology or who were treated with palliative radiation, median 
CFI was 14.2 months (range 4.7 – 33.0). Radiation was well tolerated with 2 (12.0%) experiencing grade 3/4 
gastrointestinal/genitourinary toxicities. In conclusion, radiation to treat locally recurrent vaginal/perirectal 
lesions in heavily pre-treated OC patients is safe and may effectively provide IFC.   
1. Introduction 
Despite recent advances in primary and maintenance therapies for 
patients with ovarian carcinoma (OC), over 80% will recur and experi-
ence treatment-related toxicities. The landscape of therapeutic options 
in the recurrent setting is driven by platinum response, and most 
commonly includes systemic therapies such as chemotherapy, biologic 
targeted therapies, immunotherapy, and even endocrine therapy (NCCN 
Guidelines, 2020). Prior to the development of effective palliative 
chemotherapy options, pelvic radiation was used for local control (Firat 
and Erickson, 2001). However, this modality fell out of favor because it 
failed to address upper abdominal disease, while whole abdomen radi-
ation produced toxicities that outweighed its limited benefits. Never-
theless, while current guidelines reserve a role for localized radiation to 
palliate symptoms, (NCCN Guidelines, 2020) it remains unclear who 
benefits most from this localized treatment modality. 
The small, but growing body of literature on radiation for recurrent 
OC has documented responses in heterogeneous populations with oli-
gometastatic disease (i.e. vaginal/rectal implants vs. localized nodal and 
extranodal recurrences in the abdomen and/or pelvis) with limited 
insight into which subgroups experience clinical benefit (Firat and 
Erickson, 2001; Albuquerque et al., 2016; Chundury et al., 2016; 
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Westhoff et al., 2016; Kim et al., 2019; Brown et al., 2013; Yahara et al., 
2013; Chang et al., 2018; Smart et al., 2019; Onal et al., 2020). Though 
the reported incidence of oligometastatic vaginal/perirectal OC re-
currences appears low, (Casey et al., 1996) these areas are unique in that 
they may be salvaged with targeted radiation to improve not only local 
control and long-term survival, but also to effectively palliate symptoms. 
Thus, we aimed to better define the patient population with vaginal/ 
perirectal oligometastatic OC recurrences who benefits from radiation 
and what toxicities may result from this treatment modality. Here, we 
describe our institutional experience utilizing intensity modulated ra-
diation therapy (IMRT) +/- high dose-rate (HDR) brachytherapy to treat 
vaginal and perirectal recurrences in OC patients. Our primary objec-
tives were to evaluate complete response rates of targeted lesions after 
radiation and calculate the 5-year in-field local control (IFC) rate. Sec-
ondary objectives were to assess radiation-related toxicities, as well as 
post-radiation progression-free survival (PFS) and overall survival (OS). 
2. Methods 
This case series included 17 patients with recurrent OC who received 
IMRT, HDR brachytherapy, or both for vaginal and/or perirectal re-
currences at Washington University School of Medicine from January 
2006 to November 2019. Eligible patients were identified from our 
Radiation Oncology institutional database. Initial treatment planning, 
simulation, treatment devices, and radiation treatment plans were 
individualized at the discretion of the treating radiation oncologist. This 
retrospective review was approved by the Washington University 
Institutional Review Board (#202005019). 
We included patients with recurrent OC, regardless of stage or his-
tology, with a vaginal and/or perirectal recurrence as determined by 
computed tomography (CT), 18-fluoro-deoxyglucose positron emission 
tomography (FDG-PET), and/or magnetic resonance imaging (MRI). 
Patients were subdivided by oligometastatic, defined as 1–5 metastatic 
lesions, (Lievens et al., 2020) or multi-site recurrence prior to radiation. 
Following radiation, patients were seen for 6-week post-radiation 
exams by either a radiation oncologist or gynecologic oncologist, and 
thereafter according to systemic treatment schedules, but at least every 
3 months. Radiation related toxicities were categorized as acute (≤28 
days) or late (>28 days) and graded per common terminology criteria 
for adverse events (CTCAE) version 5.0 (Cancer Therapy Evaluation 
Program (CTEP), 2017). All patients were followed until death or time of 
analysis. 
OS was defined from start of radiation to death or last follow-up at 
time of analysis. PFS was defined from start of radiation to progression 
(evidenced by imaging or initiation systemic therapy), death, or last 
follow-up at time of analysis. IFC was defined as no recurrence within 
the radiated field as determined by PET/CT, CT, MRI, or clinical exam. 
Those suspected of recurrence following radiation did not require biopsy 
for histologic confirmation. Chemotherapy-free interval (CFI) was 
calculated as the time between radiation start and next line of chemo-
therapy. OS, PFS, and IFC were calculated using Kaplan-Meier method. 
The log rank test was used to compare PFS and OS after radiation 
stratified by pre-radiation platinum status. All tests were two-sided with 
a significance level of 0.05. SAS Version 9.4 (Cary, NC) was used to 
perform all statistical analyses. 
3. Results 
A total of 17 patients were included in the analysis, 4 with oligo-
metastatic disease and 13 with multi-site disease. Table 1 summarizes 
patient clinical characteristics. All but 2 patients were white, the median 
age at diagnosis was 58 (range 38–77), and most had stage III disease 
and high-grade serous histology. Of the 12 patients with available ge-
netic testing results, 2 had germline mutations in BRCA2, 1 in BRCA1, 
and 1 in MLH1. All 4 (23.5%) patients (ID 10, 11, 16, and 17) with 
oligometastatic disease confined to the vagina/rectum were initially 
platinum sensitive, but only 3 were platinum sensitive immediately 
preceding radiation. 
Table 2 summarizes treatment characteristics of patients stratified by 
oligometastatic and multi-site recurrence. Overall, this was a heavily 
pretreated population. Patients had received a median of 3 lines of 
chemotherapy prior to radiation (range 1–9), including 3 who received 
concurrent chemoradiation. Eleven of the 17 patients received definitive 
radiation; median time for radiation completion was 41 days (range 
11–105). One patient (ID 17) experienced extended time to completion 
of a total of 105 elapsed days—45 days for initial photon treatment, 
6000 cGy in 30 fractions, followed by proton boost, 30 cobalt gray 
equivalents (CGE) in 15 fractions. This plan was specifically individu-
alized for this patient, as she was the only one in our series who received 
proton therapy. The two patients with the longest CFI after radiation 
included a BRCA2 mutation carrier (ID 11) with isolated disease to the 
vagina, while the other (ID 14) had a mismatch repair deficient (MLH1) 
tumor treated with concurrent radiation and pembrolizumab. 
Median follow-up after radiation was 28.4 months (range 
4.5–166.4). Fifteen (88.2%) patients achieved a complete response of 
targetable lesion(s) after radiation. Four (23.5%) patients (ID 8, 6, 11 
and 10) had in-field failures at 3.7, 11.2, 24.5, and 27.5 months after 
start of radiation (Fig. 1). Two were BRCA carriers, and 3 received 
additional radiation to the vaginal cuff/perirectal area. A detailed 
narrative of these 4 patients and their management strategies are pro-
vided in Supplemental Table 1. Eleven women were treated with cura-
tive intent, and among them, 7 (64%) were free of disease within the 
treatment field at last follow-up. Ten patients were evaluable for 5-year 
follow-up after radiation, contributing to a 5-year IFC rate of 70%. 
At the time of this analysis, 3 (17.6%) patients were alive with no 
evidence of disease, 2 (11.8%) were alive with disease, and 12 (58.8%) 
were dead of disease. Overall median PFS post-radiation was 11.0 
months (range 2.6–27.5). Patients treated with definitive intent (n =
11), had a 13.4 month longer median PFS than those treated with 
palliative doses (18.6 vs 5.2 months, p = 0.01). PFS did not differ when 
stratified by platinum status prior to radiation. The 9 patients who were 
platinum-sensitive prior to radiation had similar median PFS (6.5 vs. 
13.4 months, log-rank p = 0.75), but longer OS (71.1 vs 18.8 months, 
log-rank p = 0.05, Fig. 2) compared to their platinum-resistant coun-
terparts. Excluding patients with low-grade serous histology and those 
who were treated with palliative intent, the median CFI was 14.2 
months (range 4.70–33.0) with no impact on PFS or OS when stratified 
by CFI < 12 months vs. ≥ 12 months. 
Overall radiation was well tolerated with 2 patients experiencing 
grade 3/4 toxicities. Patient 12 had a vesicovaginal fistula repair 5 
months prior to radiation and the fistula recurred during her last week of 
radiation for multisite disease (vaginal cuff and retroperitoneal aden-
opathy). Patient 5 was diagnosed with a parastomal hernia and bowel 
perforation outside of the radiated field approximately 4 weeks after 
completing palliative pelvic IMRT + HDR brachytherapy for multi-site 
disease. This was thought to be due to a 10 cm mass eroding into the 
colon and she eventually succumbed from this event. 
4. Discussion 
Focused radiation therapy led to durable IFC for most OC patients 
with recurrence involving the vaginal apex and/or perirectal area. As 
expected, genitourinary and gastrointestinal side effects were most 
frequent, but grade 3–4 complications were uncommon. However, OS 
was determined by platinum sensitivity, suggesting that subsequent 
chemotherapy plays a role in determining survival. Our results support 
continuing our ongoing institutional practice to evaluate patients with 
limited metastatic burden for targeted radiation with the goal of 
providing treatment breaks from systemic therapy, palliation of symp-
toms, and effective locoregional control. 
Prior studies exploring localized radiotherapy, including our own 
institutional data from 2016, historically included heterogeneous 
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populations of OC patients, many with localized nodal and extranodal 
recurrences in the abdomen and/or pelvis (Albuquerque et al., 2016; 
Chundury et al., 2016; Westhoff et al., 2016; Kim et al., 2019; Brown et al., 
2013; Yahara et al., 2013; Chang et al., 2018; Smart et al., 2019; Onal 
et al., 2020). Nevertheless, rates of local control at 2 and 3 years after 
radiation are > 80% and 5-year IFC rates as high as 71% (Albuquerque 
et al., 2016; Brown et al., 2013). More recently, the SABR-COMET trial 
reported a 5-year OS benefit among patients with metastatic solid tumors 
treated with palliative radiation vs ablative therapy (17.7% vs. 42.3% 
,95% CI, 28–56%; p = 0.006), with no new grade 2–5 adverse events or 
differences in quality of life (Palma et al., 2020). Though this study 
excluded gynecologic oncology patients, our study results show compa-
rable rates of 5-year in-field control (70%) when targeted local radiation 
therapy is employed in this patient population. Importantly, due to the 
anatomic location of tumors in this study, patients experiencing in-field 
recurrence were frequently salvaged with additional radiation. Of the 
17 patients in our case series, four had undergone a diverting ostomy prior 
to initiation of radiation, either as a part of their upfront staging surgery 
(n =1) or during a secondary cytoreductive surgery (n = 3). Nevertheless, 
no patients underwent a diverting procedure after radiation completion. 
Collectively, this data suggests that in carefully selected women with 
recurrent OC localized to the pelvis and involving the vagina and/or 
perirectal area, there may be a potential advantage to delivering 
aggressive local radiation. This can be administered with limited toxicity, 
and provide heavily pretreated patients treatment breaks from systemic 
therapy. Furthermore, we show a median CFI post-radiation of 14.2 
months, which for platinum-resistant patients, could lead to re-challenge 
with a platinum or additional agents. 
Table 1 
Summary of clinical characteristics.  
ID Age at RT 
(years) 
Race Histology Stage Genetics Optimally Debulked 
(<1cm) 










(39–81)  White 
(15) 
HG Serous (9) 
LG Serous (2) 



















1 81 White HG Serous IIIb Unknown No Vaginal apex, Left para- 
aortic LN 
53 Sensitive Resistant 
2 61 White HG Serous IIIc Unknown No Vaginal apex, Right 
external iliac LN 
73 Sensitive Sensitive 
3 78 Asian Clear cell Ic Negative* No Vaginal apex, three 
abdominal & pelvic 
masses, RP LN 
18 Sensitive Sensitive 
4 49 White LG Serous IVb Unknown No Vaginal apex, 
Peritoneum, Serosa, Left 
inguinal, Mediastinum 
149 Sensitive Sensitive 
5 66 White HG Serous IIIc Unknown No Vaginal apex (involving 
bladder & sigmoid 
colon), Left iliac LN 
Mesenteric implants 
74 Sensitive Resistant 
6 79 White HG Serous IIc BRCA1 No Vaginal apex, Left 
external iliac LN 
148 Sensitive Sensitive 
7 80 White HG Serous IVb Unknown No Vaginal apex, hilum, 
Inguinal LN 
36 Resistant Resistant 
8 75 White LG Serous IIIc Negative 
BRCA1/2 
Yes Vaginal apex, Pelvis 135 Sensitive Resistant 
9 67 White HG Serous IIIc Negative 
BRCA1/2 
No Vaginal apex, L SVC, 
Lung, 
Left abdominal wall, LNs: 
Left PA, Right inguinal, 
Right external iliac 
113 Sensitive Sensitive 
10 79 White HG Serous IIIc Negative* Yes Vaginal apex 35 Sensitive Sensitive 
11 53 White Gr 3 Endometrioid and HG 
Serous 
Ib BRCA2 Yes Vaginal apex 81 Sensitive Sensitive 
12 59 White Carcinosarcoma IVa Negative* No Vaginal apex, RP 
adenopathy 
9 Refractory Refractory 
13 57 Black HG Serous IIIc BRCA2 Yes Vaginal fornix, Spleen, 
Liver, 
Left iliac, Peritoneum, 
Left rectus 
78 Sensitive Sensitive 
14 39 White Clear cell Ic MLH1 Yes Vaginal apex, LNs: RP, 
Left iliac 
10 Resistant Resistant 
15 56 White Carcinosarcoma 
(HG Serous) 
IIIc Negative* Yes Vaginal apex, bladder 
dome, 
Left iliac 
75 Sensitive Resistant 
16 74 White HG Serous IIIc Negative* Yes Perirectal & Vaginal apex 87 Sensitive Sensitive 




Yes Vaginal apex 139 Sensitive Resistant 
RT: radiation; Dx: diagnosis; HG: high-grade, Gr: grade; LG: low-grade; LN: lymph node; RP: retroperitoneal. 
* Patients were screened with a multi-gene panel.  
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Table 2 
Treatment and outcomes.  




RT modality Intent of 
RT 














10 2 HDR Brachytherapy 
(Vaginal cylinder), 
IMRT 
Definitive Yes 1000, 6000 500, 200 Yes No 52.6 Alive with 
disease 
11 2 IMRT Definitive Yes 6000 200 Yes No 38.2 Alive 
without 
disease 
16 3 IMRT Definitive Yes 5940 180 No No 16.6 Dead 
17 3 IMRT Definitive Yes 6000 200 No No 7.6 Alive with 
disease 
Multisite disease: IMRT + HDR Brachytherapy 
5 8 HDR Brachytherapy 
(Vaginal cylinder), 
IMRT 
Palliative Yes 1000, 5040 500, 180 No Yes 4.5 Dead 
12 1 HDR Brachytherapy 
(Vaginal cylinder), 
IMRT 
Definitive Yes 1000, 6000 500, 200 No Yes 14.0 Dead 
15 3 HDR Interstitial 
brachytherapy, IMRT 
Definitive Yes 1800, 5940 225, 180 No No 16.5 Dead 
Multisite disease: IMRT alone 
1 4 IMRT Definitive Yes 5040 180 No No 38.0 Dead 
8 4 IMRT# Definitive Yes* 5040 180 Yes No 58.8 Dead 
2 1 IMRT Definitive Yes 6000 200 No No 69.8 Dead 
3 1 IMRT Palliative No, concurrent 
carboplatin & 
paclitaxel 
5040 180 No No 89.1 Alive 
without 
disease 
4 5 IMRT Palliative Yes 5000 200 No No 28.5 Dead 
9 9 IMRT Palliative Yes 6000 200 No No 28.7 Dead 
13 8 IMRT Palliative Yes 6000 200 No No 26.0 Dead 
Multisite disease: HDR Brachytherapy alone 
6 1 HDR Brachytherapy 
(Vaginal cylinder)# 
Definitive Unknown^ 2400 400 Yes No 166.4 Dead 
7 2 HDR Brachytherapy 
(Vaginal cylinder) 
Palliative No, concurrent 
bevacizumab/ 
pemetrexed 
4800 800 No No 4.7 Dead 
14 1 HDR Brachytherapy 
(Vaginal cylinder) 
Definitive No, concurrent 
pembrolizumab 
4800 800 No No 20.6 Alive 
without 
disease  
Fig. 1. Kaplan-Meier estimates of IFC, PFS, and OS among recurrent ovarian cancer patients treated with radiation.  
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Our case series has several limitations impacting interpretation of 
data and extrapolation to the recurrent OC patient population at large. 
Given the small sample size and high rates of complete response to ra-
diation, we were unable to perform subgroup analyses to better under-
stand predictors of complete response to radiation and 5-year IFC. 
Though platinum status prior to radiation was collected, subgroup 
analysis was not feasible to further explore the impact of platinum- 
sensitivity to radiation response and IFC. Our small sample size also 
did not allow for meaningful comparisons between different radiation 
modalities (IMRT versus brachytherapy), dose, and volumes for optimal 
tumor response, nor could we stratify by important clinical character-
istics such as tumor number, size, or location (vaginal apex/perirectal 
area vs other), histology, number of therapies prior to radiation, and 
genetic status. Additionally, although radiation was generally well 
tolerated, we do not have quality of life data for this cohort to determine 
symptomatic benefit from radiation. 
Future studies should examine utilization of other modalities to 
deliver aggressive local radiation to locally recurrent OC patients as 
employed in this study. Our institution is actively examining stereotactic 
radiation utilizing MRI-guidance and adaptive treatment planning to 
test whether this approach can provide patients with shortened treat-
ment times (days instead of weeks) while maintaining desired clinical 
outcomes for treatment sites throughout the body without increasing 
adverse events. Additionally, the timing of radiation in relation to 
chemotherapy should be investigated. At present, there is no consensus 
regarding initiation of radiation in patients with locoregional recur-
rence. In our study, time from diagnosis to first round of radiation 
therapy was > 5 years. Potentially, initiation of local therapy earlier in 
the treatment course could provide greater therapeutic benefit, while 
simultaneously reducing cumulative treatment-related toxicity and 
improving quality of life outcomes. Finally, it will be important to 
identify any clinical (platinum sensitivity, histology, etc.) or genetic 
markers (tumor mutational burden, BRCA status) within the population 
that may predispose patients to greater benefit from aggressive local 
therapy. 
In conclusion, our data suggests that utilization of aggressive local 
therapy with radiation for patients with locoregional pelvic recurrence 
is safe, provides effective IFC, leading to increased CFI, with minimal 
gastrointestinal/genitourinary side effects. We propose that radiation 
should be considered for appropriately selected patients at the time of 
locoregional pelvic recurrence as it may lead to improved clinical 
outcomes. 
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